GLORIOSA is a phase 3 trial comparing mirvetuximab soravtansine, an antibody-drug conjugate targeting folate receptor alpha, with chemotherapy in ovarian cancer patients. In the BRCAm cohorts, a high proportion of patients achieved a CA-125 response and complete response (CR), with a CA-125 CR rate of 60% and 68% in the 120 - Featured Poster Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer Floor. This drug is used when a person's cancer was previously treated with at least one systemic therapy. ）用于治疗FRα（叶酸受体α）阳性、铂耐药上皮性卵巢癌、输卵管癌、原发性腹膜癌成人患者，这些患者既往接受过 1-3 线系统性治疗。. Mirvetuximab soravtansine-gynx led to a clinically meaningful and statistically significant improvement in progression-free survival, overall survival, and objective response rate vs single-agent. The aim of this study was to develop a population pharmacokinetic model to describe the concentration-time profiles of mirvetuximab soravtansine, the payload (DM4) and a metabolite (S-methyl-DM4). WALTHAM, Mass. In Indian cities, house numbers and street names are mostly unencumbered by logic. Folate receptor alpha expression predicted benefit from mirvetuximab soravtansine in platinum-resistant high-grade serous epithelial ovarian, primary peritoneal or fallopian tube cancers. ABOUT ELAHERE® (mirvetuximab soravtansine-gynx) ELAHERE is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. investigator's choice chemotherapy: analysis from the phase 3 MIRASOL trial In the FRα-high population, the LS mean overall change of mirvetuximab soravtansine from chemotherapy was 633; 95% CI, 163; P = An analysis of FOSI scores found that by. If you want to retire earlier than the traditional retirement age, this "Financial Freedom Fund" calculator will tel. In the BRCAm cohorts, a high proportion of patients achieved a CA-125 response and complete response (CR), with a CA-125 CR rate of 60% and 68% in the 120 - Featured Poster Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer Floor. Mirvetuximab soravtansine-gynx is available as Elahere (ImmunoGen, Inc. NCI supports clinical trials that test new and more effective ways to treat cancer. MIRV has demonstrated promising single agent activity in ovarian cancer, especially in tumors with high FRα expression,. Based on findings from the phase 3 MIRASOL trial, investigators plan to submit a supplemental biologics license application for mirvetuximab soravtansine in folate receptor α-positive platinum-resistant ovarian cancer. family medicine consultant jobs middle east Moore, MD, associate director of clinical research at Stephenson Cancer Center, director of the Oklahoma TSET Phase I Program, and professor in. Mirvetuximab Soravtansine This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) comprising an FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent that has consistently shown clinically meaningful single-agent activity, along with favorable tolerability, in patients with high FRα expressing tumors (Moore ESMO 2019 The recommended mirvetuximab soravtansine-gynx dose is 6 mg/kg adjusted ideal body weight administered once every 3 weeks (21-day cycle) as an intravenous infusion until disease progression or unacceptable toxicity. Listing a study does not mean it has been evaluated by the U Federal Government. Topline findings from the phase 2 PICCOLO trial support the potential use of mirvetuximab soravtansine for the treatment of folate receptor alpha-positive, platinum-sensitive ovarian cancer. Mar 22, 2024 · On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. Mirvetuximab soravtansine is indicated for the treatment of adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the. Video Summary of Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. The ADC is being developed by ImmunoGen for the treatment of FRα expressing cancers. Introduction: Mirvetuximab soravtansine (mirvetuximab) is an antibody drug conjugate (ADC) comprised of a humanized folate receptor alpha (FRα)-binding monoclonal antibody attached via a cleavable linker to the cytotoxic maytansinoid molecule, DM4. Mirvetuximab soravtansine is an ADC that targets FRa and was approved by the FDA in November 2022. The mirvetuximab soravtansine plus bevacizumab doublet is an active and well-tolerated regimen in patients with FRα-expressing platinum-resistant ovarian cancer. Learn about premedication, dosing, administration, and dosage modification guidelines. In November 2022, mirvetuximab soravtansine was approved in the. Methods: We conducted a phase 3, global, confirmatory, open-label, randomized, controlled trial to compare the efficacy and. The investigators concluded, "Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with mirvetuximab soravtansine showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response Dr. Mirvetuximab soravtansine is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent. Mirvetuximab soravtansine-gynx (Elahere) is a folate receptor alpha (FR)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult individuals with FR positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one (1) to three (3) prior systemic treatment regimens. Methods: 453 PROC pts with high FRα expression. Mirvetuximab soravtansine is an ADC that targets FRa and was approved by the FDA in November 2022. Some people have more control over the Most people know th. craigslist cars and trucks for sale by private owner On November 14, 2022, the FDA granted accelerated approval to mirvetuximab soravtansine-gynx for treatment of adult patients with folate receptor-α (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic therapies. Click here to read my thoughts on this deal. The randomized, open-label, phase III study FORWARD I compared MIRV and investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian cancer (EOC). Chicago is the third-largest city in the. Short answer: Yes. Mirvetuximab soravtansine showed a 5125 months median DOR in the PICCOLO trial. Mirvetuximab is composed of an antibody against folate receptor alpha (FRα), a cleavable disulfide linker, and an anti-tubulin DM4 payload. Mirvetuximab soravtansine-gynx（Elahere™） Elahere 是由ImmunoGen公司研发的一款靶向FRα的抗体偶联药物，通过可裂解的二硫键将靶向FRα的人源性单克隆抗体与具有细胞毒性的效应分子DM4连接起来。每个抗体分子与平均3-4个DM4分子偶联，该药物通过抗体部分特异性识别卵巢. 1 Supporting data for this approval came from the phase 3 MIRASOL trial (NCT04209855). 46 months (95% CI, 1457) vs 12. Mirvetuximab soravtansine. 1) RxDx Assay (Ventana Medical Systems, Inc. Elahere (mirvetuximab soravtansine) is a targeted anticancer medication called an antibody-drug conjugate (ADC). This agent has shown against advanced epithelial ovarian cancer, including disease that is platinum-resistant. All patients received a 200. , March 22, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U Food and Drug Administration (FDA) has granted full approval for ELAHERE ® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal. Patients with advanced, FRα-positive TNBC were enrolled on. Apr 24, 2024 · Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option. spanish decor No information is available on the clinical use of mirvetuximab soravtansine during breastfeeding. The FDA has granted a priority review for ImmunoGen's Biologics License Application (BLA) for its investigational antibody-drug conjugate, mirvetuximab soravtansine, as a monotherapy for patients with previously treated folate receptor alpha-high platinum-resistant ovarian cancer. The decision to grant full approval was made after reviewing the results of the MIRASOL. Warning. Summary of Use during Lactation. This application was granted priority review. In November 2022, mirvetuximab soravtansine was approved in the USA for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. 4 INVESTIGATOR'S AGREEMENT I have received and read the Investigator Brochure for mirvetuximab soravtansine. MIRASOL is a randomized phase 3 trial to confirm the efficacy of MIRV vs standard-of-care chemotherapy in patients (pts) with PROC. In the case of platinum resistance and sensitivity in patients with folate receptor alpha (FRα)-expressing tumors, research suggests that mirvetuximab soravtansine is an effective treatment option As a monotherapy, mirvetuximab has achieved confirmed objective responses in 24% to 47% of patients with high FRα tumors. When combined with. ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. WALTHAM, Mass. Please see Full Prescribing Information, including Boxed WARNING. Elahere (Mirvetuximab soravtansine-gynx) is a FRα - Directed Antibody Drug Conjugate, this Antibody is a type of Chimeric IgG1. 20 FRα is a membrane protein that binds to and transports folate into cells. 1) RxDx Assay is the first and only immunohistochemistry (IHC) assay FDA approved to identify epithelial ovarian cancer (EOC) patients eligible for FOLR1-targeted treatment with ELAHERE (mirvetuximab soravtansine). If you experience any of the following symptoms, call your doctor immediately: vision changes, dry eye, light sensitivity, eye pain, eye redness, excess tearing or discharge from the eye, difficulty opening the eyelid because of pain, blurred vision, or feeling like something is in your eye. Mirvetuximab soravtansine-gynx can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis. ELAHERE® (mirvetuximab soravtansine-gynx) injection, for intravenous useS. Apr 24, 2024 · Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option. What are the ingredients in ELAHERE? Active ingredient: mirvetuximab soravtansine-gynx Inactive ingredients: glacial acetic acid, polysorbate 20, sodium acetate, sucrose, Water for Injection. Analysis was conducted across 3 studies to understand the impact of pt characteristics on the PK parameters of MIRV, DM4, and S-methyl-DM4 (SmDM4) metabolite in pts with FRα-positive. Patients are selected for therapy based on an FDA-approved test.

Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across. The FDA has accepted a biologics license application for mirvetuximab soravtansine under priority review for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic therapies, according to a press release from the drug's developer ImmunoGen. Because mirvetuximab is a large protein molecule with a molecular weight of 150,000 Da, the amount in milk is likely to be very low. I have read the ImmunoGen Protocol IMGN853-0417 and agree to conduct the study as outlined PICCOLO is a single arm Phase 2 trial evaluating the efficacy and safety of mirvetuximab soravtansine monotherapy in patients with FR-alpha high platinum-sensitive ovarian cancer who have received. revoli construction The combination of mirvetuximab soravtansine and bevacizumab was evaluated in patients with FRα-positive (medium/high expression; ≥ 50%/≥ 75% of cells with PS2+ staining intensity), platinum-agnostic. No information is available on the clinical use of mirvetuximab soravtansine during breastfeeding. Manufactured by: ImmunoGen, Inc. Mirvetuximab soravtansine-gynx may have the potential to become a new standard for patients with folate receptor α-positive, platinum-resistant ovarian cancer, experts say. Your healthcare provider will perform a test to make sure that ELAHERE is right for you. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience. 2 toggle 1 rocker switch plate Mirvetuximab soravtansine is a cancer drug for adults with ovarian, fallopian, or peritoneal cancer who have not responded to other treatments. It has been granted accelerated approval based on results from the SORAYA trial, a single-arm study in 106 patients with platinum-resistant ovarian cancer whose tumors expressed high. In November 2022, mirvetuximab soravtansine was approved in the. 62 months in the mirvetuximab soravtansine arm and 3 Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere ™) is an antibody-drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody conjugated to a microtubule inhibitor via a cleavable linker. Intravenous route (Solution) Warning: Ocular ToxicityMirvetuximab soravtansine-gynx can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis. In November 2022, mirvetuximab soravtansine was approved in the. Mirvetuximab soravtansine approved under the brand name ELAHERE® in the United States has received regulatory approval in adults with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for. Your paycheck includes a variety of deductions for federal and state taxes and perhaps local. jennings chevrolet That includes some that play a role in cancer. Among 106 patients enrolled, 105 were evaluable for efficacy4% (95% CI. Mirvetuximab soravtansine-gynx is a folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC) consisting of three components: 1) an anti-FRα monoclonal antibody of IgG1 subtype 2) the. Mirvetuximab soravtansine was granted accelerated approval by the US FDA on November 14, 2022, for the treatment of adult patients with FRα positive, platinum-resistant. Background: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States. The first was a dose escalation and expansion study to evaluate the safety and tolerability where the recommended phase 2 dose (RP2D) was determined. A review of 4 key studies involving 453 participants consistently demonstrates mirvetuximab soravtansine's clinically meaningful antitumor.

Ovarian cancer, ranked as the second leading cause of gynecologic malignancy-related deaths globally, poses a formidable challenge despite advances in early detection and treatment modalities. The small molecule anti-tubulin agent, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker Mirvetuximab soravtansine (IMGN853) is an ADC comprised of a humanized anti-FRα monoclonal antibody (M9346A) linked to a cytotoxic effector molecule, the maytansinoid DM4. Background: Mirvetuximab soravtansine (MIRV), an antibody drug conjugate targeting FRa, demonstrated clinically meaningful antitumor activity in a single arm trial reported previously (Matulonis, JCO 2023). Mirvetuximab soravtansine is an antibody-drug conjugate comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and maytansinoid DM4 payload, a potent tubulin-targeting antimitotic agent [12]. Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine). One example is a monoclonal antibody recently approved by the Food and Drug Administration (FDA) called mirvetuximab soravtansine for people with ovarian cancer recurrence. No information is available on the clinical use of mirvetuximab soravtansine during breastfeeding. Effective July 1, 2023, the permanent J-Code for ELAHERE is J9063 - Injection, mirvetuximab soravtansine-gynx, 1 mg The Centers for Medicare & Medicaid Services (CMS) released the April 2023 Quarterly Healthcare Common Procedural Coding System (HCPCS) file, which includes the designation of J9063 for injection, mirvetuximab soravtansine. Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate composed of an antifolate receptor α (FRα) monoclonal antibody, a cleavable linker, and the maytansinoid DM4 payload, a potent tubulin-targeting antimitotic agent. Mar 22, 2024 · On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. In November 2022, mirvetuximab soravtansine was approved in the USA for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. Researchers are combining bevacizumab with new drugs to improve outcomes. Mirvetuximab soravtansine combines a folate receptor alpha-binding antibody linked to the tubulin-disrupting maytansinoid DM4. ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. Learn about its uses, cost, dosage, side effects, and more. As part of the Phase 1b FORWARD II trial (NCT02606305), the combination of MIRV with bevacizumab (BEV) was evaluated in pts with FRα-positive (medium/high expression; ≥ 50%/ ≥75% of cells with PS2+ staining intensity. It is often administered once every three weeks. To the editor: Matulonis et al 1 conducted an important single-arm study to evaluate the efficacy and safety of mirvetuximab soravtansine for treating platinum-resistant ovarian cancer. Apr 24, 2024 · Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option. Here's one travel journalist's review of a recent stay. Background: Mirvetuximab soravtansine (MIRV) is an ADC comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. More than 90% of ovarian cancers overexpress FRα, a biomarker for worse clinical outcomes, and about 30% to 35% of patients overexpress. If you’ve been thinking about visiting Greece this year, now's. pizza business for sale bc [now a part of AbbVie]) for adult patients with FRα positive, platinum. In a phase I basket trial, mirvetuximab demonstrated efficacy in patients with solid tumors including EOC and endometrial cancer. Mirvetuximab soravtansine-gynx is approved to treat: Ovarian epithelial, fallopian tube, or primary peritoneal cancer that is folate receptor–alpha positive. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2022; Chicago, IL The results presented at ASCO 2021 build on previously published data showing that mirvetuximab soravtansine was well tolerated and produced a confirmed objective response rate (ORR) of 39% Background: Elevated FRα expression is characteristic of a number of solid tumors, including EOC and endometrial cancer, thereby providing an attractive candidate for targeted therapeutic strategies in these indications. Your healthcare provider will perform a test to make sure that ELAHERE is right for you. Jakelin died two days after she and her father turned themselves in to border patrol agents, seeking asylum. Patients are selected for therapy based on an FDA-approved test. Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. In November 2022, mirvetuximab soravtansine was approved in the USA for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. [now a part of AbbVie]) for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one. Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate composed of an antifolate receptor α (FRα) monoclonal antibody, a cleavable linker, and the maytansinoid DM4 payload, a potent tubulin-targeting antimitotic agent. Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate targeting folate receptor α (FRα). See full prescribing information for complete boxed warning Based on an earlier analysis of SORAYA, 2 the first-in-class mirvetuximab soravtansine was approved by the U Food and Drug Administration in November 2022 for patients with high levels of FRα expression. Mirvetuximab soravtansine-gynx is not compatible with normal saline and must be diluted in 5% dextrose. The Marketing Authorization Application (MAA) for. Purpose: To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug conjugate comprising a humanized anti-folate receptor alpha (FRα) monoclonal antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent, in combination with bevacizumab in patients with FRα-positive, platinum-resistant ovarian cancer. Elahere (Mirvetuximab Soravtansine) is classified as a prescription pharmaceutical drug. -- (BUSINESS WIRE)--May 19, 2021-- ImmunoGen Inc. Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), a biomarker that is commonly overexpressed on ovarian carcinomas and. Josh Constine test drives the Arx Pax Hendo Hoverboard Don’t be surprised if the next rumor out of Cupertino is that the new gold iPhones are forged from the company’s own melted-down ingots: Apple is richer than ever Some types of policing can be big business for police departments and towns, but they do little to reduce crime. glendale crips Mirvetuximab soravtansine has shown activity in biomarker-selected patients with platinum-resistant ovarian cancer, according to study results published in the Journal of Clinical Oncology About. This drug is used when a person's cancer was previously treated with at least one systemic therapy. Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens Abstract. Mirvetuximab soravtansine is an ADC comprising an IgG1 monoclonal antibody against the folate receptor alpha (FRα) conjugated to the cytotoxic maytansinoid effector molecule DM4 that has shown promising clinical activity in patients with FR-α-positive ovarian cancer. Methods: A comprehensive search was conducted on online databases, including PubMed, Cochrane Library, and EMBASE, to identify relevant literature about the efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with. Mirvetuximab soravtansine (mirvetuximab soravtansine-gynx; Elahere ™) is an antibody-drug conjugate (ADC), which is comprised of a folate receptor α (FRα) directed antibody conjugated to a microtubule inhibitor via a cleavable linker. 11, 17 IMGN853 binds with high affinity and specificity to FRα, which upon antigen binding, promotes ADC internalization and intracellular release of DM4 In this regard, mirvetuximab soravtansine (IMGN853) is an ADC comprising a humanized FRα-binding monoclonal antibody conjugated to the cytotoxic maytansinoid effector molecule DM4. Elahere is a first-in class antibody drug conjugate directed against FRα, which is cell-surface protein highly expressed in ovarian cancer. Listing a study does not mean it has been evaluated by the U Federal Government. 20 FRα is a membrane protein that binds to and transports folate into cells. As the sun sets earlier and the temperatures get cooler, you're likely already d. HCP administered medications are sold and given to you by your physician. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab, may be an alternative treatment for recurrent platinum-sensitive ovarian cancer. 近日，美国食品与药品监督管理局（FDA）批准mirvetuximab soravtansine-gynx（Elahere™，ImmunoGen, Inc. In November 2022, mirvetuximab soravtansine was approved in the USA for. Abstract. For gynecologic cancer, mirvetuximab soravtansine induces ICD in vivo, as shown by the upregulation of ICD markers. Because mirvetuximab is a large protein molecule with a molecular weight of 150,000 Da, the amount in milk is likely to be very low. ABOUT IMMUNOGEN Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate composed of an antifolate receptor a (FRa) monoclonal antibody, a cleavable linker, and the may-tansinoid DM4 payload, a potent tubulin-targeting anti-mitotic agent. Google Reader recently added custom "Send To" controls to its feature list, and we've been looking for the most useful links to feed it. A clinical trial of mirvetuximab soravtansine, a novel antibody–drug conjugate, in patients with ovarian cancer that expresses folate receptor alpha. A new targeted therapy called Elahere (generic name mirvetuximab soravtansine) is providing much needed hope for ovarian cancer survivors who are platinum resistant. Background: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate that selectively targets folate receptor α (FRα). Methods: We conducted a phase 3, global, confirmatory, open-label, randomized, controlled trial to compare the efficacy and.